Vista Partners Updates Coverage on OncoSec Medical Inc.; Target Price $2.50
SAN FRANCISCO, Jan. 26, 2012 /PRNewswire/ — Vista Partners announced today that it has updated coverage of OncoSec Medical Inc. (OTCBB: ONCS) (“the Company”) with a twelve month target price of $2.50. Ross Silver, Principal Analyst at Vista Partners stated, “OncoSec plans to initiate three Phase II ElectroImmunotherapy studies in the first quarter of 2012 which include: Melanoma, Cutaneous T-Cell Lymphoma & Merkel Cell Carcinoma. The largest commercial market of the three targeted indications is melanoma where OncoSec’s clinical candidate OMS-I100 could eventually compete against and possibly displace market leader Bristol-Myers Squibb’s cancer drug Yervoy(TM). Yervoy(TM) is predicted to generate peak revenues of $6B according to many analysts. OMS-I100 has a ways to go prior to commercialization, however, clinical data to date is impressive and positive interim data from the planned Phase II melanoma trial could further enhance the value of this therapeutic approach.”
To download a FREE copy of the OncoSec Medical Inc. research report, please visit http://www.vistapglobal.com and click the “download research” icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm’s professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.
877.215.4813 or email@example.com
SOURCE Vista Partners LLC